Kyorin Pharmaceutical Co.,ltd.TSE: 4569

KYORIN Pharmaceutical: Q1 FY2024 delivered higher sales and profits, but FY2025 profit is forecast to decline

· Issued by Kyorin Pharmaceutical Co.,ltd.

Q1 FY2024 saw 2.0% net sales growth and a 32.0% rise in operating profit year-over-year. Full-year FY2025 guidance projects 3.2% sales growth but an 8.7% decline in profit attributable to owners, with EPS forecast at ¥87.03.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis